Vasundhara Rasayans Ltd

Vasundhara Rasayans Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 21 July 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 04 August 2026, providing investors with the latest insights into the stock’s fundamentals, valuation, financial trends, and technical outlook.

Vasundhara Rasayans Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 21 July 2026. This change reflects a combination of improved technical indicators, robust quarterly financial results, attractive valuation metrics, and a cautiously optimistic financial trend, signalling a potential stabilisation after a period of underperformance.

The 50-day moving average has crossed above the 200-day moving average for Vasundhara Rasayans Ltd, signalling a golden cross on 21 Jul 2026. Yet, the stock declined 1.81% on the same day, and monthly technical indicators remain bearish. This divergence between the moving averages and price action calls for a closer examination of the signal's reliability.

Vasundhara Rasayans Ltd has seen a marked improvement in its valuation parameters, shifting from a fair to a very attractive rating, despite ongoing challenges in the Pharmaceuticals & Biotechnology sector. With a price-to-earnings ratio of 9.54 and a price-to-book value of 1.56, the micro-cap company presents a compelling valuation case relative to its peers and historical averages.

Vasundhara Rasayans Ltd has demonstrated a remarkable financial turnaround in the quarter ended March 2026, shifting from a negative to a very positive performance trajectory. The pharmaceutical and biotechnology micro-cap company posted its highest-ever quarterly net sales and profitability metrics, signalling a potential inflection point after a period of subdued results.

Vasundhara Rasayans Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 17 Dec 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 10 July 2026, providing investors with the latest insights into its performance and prospects.

Vasundhara Rasayans Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change reflects a recalibration of market expectations amid sector headwinds and company-specific performance, offering investors a fresh perspective on the stock’s price attractiveness relative to its peers and historical benchmarks.

Vasundhara Rasayans Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Dec 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 29 June 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Vasundhara Rasayans Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from a very expensive to an expensive rating. This change reflects evolving market perceptions and impacts the stock’s price attractiveness amid a challenging sector backdrop and mixed financial metrics.

Vasundhara Rasayans Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Dec 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 18 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Vasundhara Rasayans Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from a very expensive rating to a fair valuation grade. This change, coupled with its current price-to-earnings (P/E) ratio of 13.14 and price-to-book value (P/BV) of 1.40, suggests a more attractive entry point for investors compared to its historical and peer averages.

Vasundhara Rasayans Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 June 2026, providing investors with the latest insights into its performance and outlook.

Vasundhara Rasayans Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an attractive to a fair rating. Despite a robust intraday price surge of 19.98% to ₹148.90 on 1 June 2026, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now reflect a more tempered market sentiment compared to its historical averages and peer benchmarks.

Vasundhara Rasayans Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 17 Dec 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 21 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Vasundhara Rasayans Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite ongoing sector headwinds and a challenging price performance relative to the Sensex. This repositioning is underpinned by a significant contraction in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios, suggesting a potential entry point for value-focused investors within the Pharmaceuticals & Biotechnology sector.

Vasundhara Rasayans Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift from attractive to fair, reflecting a nuanced change in investor sentiment. Despite a modest day gain of 0.27%, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now align more closely with sector averages, signalling a recalibration of its price attractiveness amid challenging market returns.